Revolutionary Treatment for Chronic Abdominal Pain: Scientists Unveil Innovative New Approach
Researchers at the University of Vienna have developed new oral peptides to treat chronic abdominal pain. Led by medicinal chemist Markus Muttenthaler, this team created gut-stable oxytocin analogues aimed at alleviating conditions like irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD).
Oxytocin, known as the “love hormone,” also plays a role in pain perception. These peptides specifically target oxytocin receptors in the gut. When they bind to these receptors, they reduce pain signals, offering a safer alternative to traditional opioid medications.
Current oxytocin is ineffective as an oral treatment because it breaks down too quickly in the digestive system. However, the new compounds are designed to remain stable in the gut while effectively activating the oxytocin receptor. This method allows patients to take their medication conveniently by mouth, unlike many peptide drugs that require injections.
Muttenthaler emphasized the promise of these gut-specific peptides as a new option for treating chronic abdominal pain. The researchers have received support from the European Research Council to further this work. They aim to bring these peptides to market, which could change how gastrointestinal diseases are treated.
What role does oxytocin play in the treatment of chronic abdominal pain?
Interview with Dr. Markus Muttenthaler: Revolutionizing the Treatment of Chronic Abdominal Pain with Gut-Stable Oxytocin Analogues
NewsDirectory3.com: We are pleased to have Dr. Markus Muttenthaler, a medicinal chemist leading a groundbreaking research team at the University of Vienna, with us today. His team has developed innovative oral peptides that could significantly change the landscape of chronic abdominal pain treatment. Thank you for joining us, Dr. Muttenthaler.
Dr. Muttenthaler: Thank you for having me!
NewsDirectory3.com: Your research focuses on using oxytocin analogues to target chronic abdominal pain. Can you explain the significance of oxytocin in this context?
Dr. Muttenthaler: Certainly! Oxytocin is often referred to as the “love hormone” due to its well-known roles in social bonding and reproduction. However, recent studies have shown that oxytocin also plays a crucial role in pain perception. Our research looked at how we could leverage this property to develop treatments that specifically target oxytocin receptors in the gut, which can help alleviate conditions like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
NewsDirectory3.com: That’s fascinating! So, what makes your newly developed compounds different from traditional oxytocin treatments?
Dr. Muttenthaler: The main challenge with current oxytocin treatments is their instability when taken orally; they break down too rapidly in the digestive system. Our gut-stable oxytocin analogues are designed to resist degradation, allowing them to effectively activate oxytocin receptors in the gut upon oral administration. This not only provides a more convenient method for patients—who can take their medication by mouth instead of through injections—but also offers a safer alternative to traditional opioid medications, which have numerous side effects and risks of dependency.
NewsDirectory3.com: That sounds like a major advancement! What are the next steps for you and your team?
Dr. Muttenthaler: We have received funding from the European Research Council, which has been instrumental in advancing our work. Our immediate goal is to conduct further research and development to refine these peptides and prepare them for clinical trials. We’ve also secured a patent for our innovations and are actively seeking investors and industry partners who can help us bring these drugs to clinical use and eventually to market.
NewsDirectory3.com: What impact do you hope this research will have on patients suffering from gastrointestinal diseases?
Dr. Muttenthaler: We hope that by providing a new, oral treatment option, we can significantly improve the quality of life for patients with chronic abdominal pain conditions. Our goal is to reduce reliance on opioids and increase accessibility to effective, convenient treatments. If successful, this research could mark a paradigm shift in how gastrointestinal diseases are treated, ultimately allowing for more personalized and less invasive therapeutic options.
NewsDirectory3.com: Thank you, Dr. Muttenthaler, for sharing your insights and updates on this exciting research. We look forward to seeing how these gut-stable oxytocin analogues evolve and the potential impact they will have in the field of medicine.
Dr. Muttenthaler: Thank you for the opportunity to discuss our work!
The team has secured a patent for their innovations and is looking for investors and industry partners to help advance these drug leads into clinical use.
Reference: “Oxytocin Verbindungen zur oralen Behandlung von Bauchschmerzen” by Thomas Kremsmayr et al., 9 October 2024, Angewandte Chemie. DOI: 10.1002/ange.202415333.